Cargando…

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review

Immune checkpoint inhibitors (ICIs) have shown durable remissions and improved long-term survival across a variety of cancer types. However, there is growing evidence that a significant subset of nonresponsive patients may exhibit hyperprogressive disease (HPD) during the initiation of immune checkp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaojun, Qiao, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Nutrition
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991276/ https://www.ncbi.nlm.nih.gov/pubmed/35399666 http://dx.doi.org/10.3389/fnut.2022.810472

Ejemplares similares

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report
por: Dong, Shixia, et al.
Publicado: (2022)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report
por: Alkader, Mohammad, et al.
Publicado: (2022)

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
por: Chen, Yan, et al.
Publicado: (2020)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
por: Long, Yaping, et al.
Publicado: (2023)

Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
por: Yan, Xuebing, et al.
Publicado: (2023)

Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
por: Wang, Mo-Xuan, et al.
Publicado: (2022)

Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors
por: Lyu, Jiahua, et al.
Publicado: (2023)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
por: Montagna, Daniela R., et al.
Publicado: (2022)

Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Li, Shuluan, et al.
Publicado: (2022)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
por: Barham, Whitney, et al.
Publicado: (2021)

Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Ni, Liwei, et al.
Publicado: (2022)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors
por: Sun, Hao, et al.
Publicado: (2022)

Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer
por: Zhang, Lilong, et al.
Publicado: (2023)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2eb3vpfstvvk4k7cde37kv6ale